Hostname: page-component-7479d7b7d-68ccn Total loading time: 0 Render date: 2024-07-12T14:19:03.592Z Has data issue: false hasContentIssue false

Doit-on limiter les contacts entre les résidents et les représentants de compagnies pharmaceutiques?

Published online by Cambridge University Press:  21 May 2015

Claude Topping*
Affiliation:
Directeur du programme de formation complémentaire en médecine d’urgence, Université Laval, Québec (Qué.)
*
Directeur du programme de formation complémentaire en médecine d’urgence, Faculté de médecine, Université Laval, Québec QC G1K 7P4; Claude.topping@mfa.ulaval.ca

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Club de Lecture JCMU • CJEM Journal Club
Copyright
Copyright © Canadian Association of Emergency Physicians 2002

References

1.Ziegler, MG, Lew, P, Singer, BC.The accuracy of drug information from pharmaceutical sales representatives. JAMA 1995; 273:12968.CrossRefGoogle ScholarPubMed
2.Wazana, A.Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 2000;283:37380.CrossRefGoogle ScholarPubMed
3.Orlowski, JP, Wateska, L.The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest 1992;102(1):2703.CrossRefGoogle ScholarPubMed
4.Chren, MM, Landefeld, CS.Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994;271(9):6849.CrossRefGoogle ScholarPubMed
5.Steinman, MA, Shlipak, MG, McPhee, SJ.Of principles and pens: attitudes and practices of medecine housestaff toward pharmaceutical industry promotions. Am J Med 2001;110(7):5517.CrossRefGoogle Scholar